Cullinan Q2 2026 earnings: Lower expenses narrow the net loss

Cullinan Therapeutics (Nasdaq: CGEM) reported a Q2 2026 net loss of $53.7 million, or $0.81 per diluted common share, compared with $70.1 million, or $1.07 per share, in Q2 2025. Lower R&D and G&A spending drove most of the improvement, while $356.0 million of cash and investments supported management’s projected runway into 2029. The next phase of the story centers on multiple autoimmune data readouts and the planned start of a potentially registrational CLN-049 study in relapsed or refractory AML.

Core financial results

Total operating expenses decreased by $18.5 million year over year, primarily because R&D expense fell by $16.6 million. Net loss narrowed by $16.4 million, with the benefit from lower operating costs partly offset by a $2.3 million decline in interest income.

The per-share loss narrowed slightly more than the net loss because weighted-average common shares increased to 61.5 million from 59.0 million.

Pipeline and business progress

Cullinan’s operating outlook depends primarily on clinical development and regulatory execution across its autoimmune and oncology portfolio.

• CLN-978: Additional multi-dose data in rheumatoid arthritis are planned for Q3 2026, followed by initial multi-dose systemic lupus erythematosus data and initial Sjögren’s disease data in Q4. Phase 2 expansions in rheumatoid arthritis, SLE and lupus nephritis are planned for early 2027.
• Velinotamig: Early observations from a China Phase 1/2 study included complete renal responses in two patients with SLE and nephritis. Additional multi-dose data are expected in Q4 2026, with a global autoimmune cytopenia basket study planned for early 2027.
• CLN-049: Following an End-of-Phase 1 meeting with the FDA, Cullinan plans to begin a potentially registrational Phase 2 study in relapsed or refractory AML during Q3 2026. A Phase 1 update and a separate combination study with venetoclax and azacitidine are planned for Q4.
• Zipalertinib: The FDA accepted the new drug application in April, with a target action date of February 27, 2027. Partner Taiho also expects top-line results from the first-line REZILIENT3 study by the end of 2026.

Cullinan is eligible for $30 million upon second-line U.S. regulatory approval of zipalertinib and up to $100 million upon first-line approval, as well as an equal U.S. profit share. These payments remain contingent on regulatory outcomes.

Liquidity and balance sheet

Cash, cash equivalents, short- and long-term investments, and interest receivable totaled $356.0 million at June 30, 2026, down from $439.0 million at December 31, 2025. The approximately $83.0 million decrease covers six months and should not be interpreted as a quarterly cash-flow figure.

Management expects current resources to fund operations into 2029 under the existing operating plan. Total liabilities were $42.0 million at quarter-end, compared with $39.6 million at the end of 2025, while stockholders’ equity declined to $321.8 million from $408.7 million.

Recent insider transactions

The supplied six-month insider summary reported eight purchase transactions covering 150,261 shares and 14 sales covering 94,492 shares, resulting in net purchases of 55,769 shares. Total insider holdings were listed at 273.49 thousand shares, with net purchases equal to 25.60% of holdings.

The latest reported entries include option exercises, stock awards and sales. They describe transactions only and do not, by themselves, establish insiders’ views on the company’s prospects.

Risks investors should monitor

• Early clinical evidence: The autoimmune programs remain in early development, and upcoming multi-dose results may not confirm the initial activity or safety observations. The disclosed velinotamig renal responses involved only two patients.
• Development execution: Cullinan plans several data readouts and new or expanded studies through early 2027. Delays in enrollment, dosing or study initiation could shift the expected catalyst schedule.
• Spending and runway assumptions: The runway into 2029 is based on the current operating plan. Expanding multiple programs could change future R&D spending and the pace of cash use.
• Regulatory dependency: CLN-049’s Phase 2 study is described as potentially registrational, not guaranteed to support approval. Zipalertinib’s milestone payments and profit-sharing opportunity also depend on successful regulatory and commercial outcomes.

Summary

Cullinan’s Q2 loss narrowed because operating expenses declined, while its liquidity position provides time to pursue a broad set of clinical milestones. The central question is now whether upcoming CLN-978, velinotamig and CLN-049 data can support advancement into larger studies without materially changing the company’s current spending and runway assumptions.